245
Participants
Start Date
October 1, 2018
Primary Completion Date
June 13, 2025
Study Completion Date
June 13, 2025
Pembrolizumab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Favezelimab
200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
Lenvatinib
20 mg lenvatinib capsules administered orally once daily
Quavonlimab
Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
National Cheng Kung University Hospital ( Site 1202), Tainan City
Hopitaux Universitaires de Geneve HUG ( Site 2106), Geneva
Vaal Triangle Oncology Centre ( Site 2314), Vereeniging
Blacktown Hospital Western Sydney Local Health District ( Site 0200), Blacktown
Wits Clinical Research ( Site 2313), Parktown-Johannesburg
Sandton Oncology Medical Group PTY LTD ( Site 2316), Sandton
Universitaetsspital Basel ( Site 2104), Basel
Gallipoli Medical Research Foundation ( Site 0202), Brisbane
Umhlanga Oncolgy Center ( Site 2311), Umhlanga
Fiona Stanley Hospital ( Site 0201), Murdoch
Kantonsspital Graubuenden ( Site 2103), Chur
Cape Town Oncology Trials Pty Ltd ( Site 2312), Kraaifontein
Universitaetsspital Zuerich ( Site 2100), Zurich
Kantonsspital St. Gallen ( Site 2102), Saint Gallen
AOU San Luigi Gonzaga di Orbassano ( Site 0707), Orbassano
National Taiwan University Hospital ( Site 1200), Taipei
Memorial Sloan Kettering Cancer Center ( Site 0113), New York
Weill Cornell Medical College ( Site 0138), New York
Taipei Veterans General Hospital ( Site 1204), Taipei
Seoul National University Bundang Hospital ( Site 0803), Seongnam-si
UPMC Cancer Center/Hillman Cancer Center ( Site 0104), Pittsburgh
University of Pennsylvania ( Site 0132), Philadelphia
Istituto Clinico Humanitas Research Hospital ( Site 0700), Rozzano
University of Maryland ( Site 0136), Baltimore
Emily Couric Clinical Cancer Center ( Site 0134), Charlottesville
Hospital Universitario Ramon y Cajal ( Site 1101), Madrid
Hospital Universitario 12 de Octubre ( Site 1102), Madrid
Mayo Clinic Florida ( Site 0115), Jacksonville
AULSS21 Regione Veneto Ospedale Mater Salutis - Legnago ( Site 0701), Legnago
Oncology Hematology Care ( Site 8005), Cincinnati
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0702), Meldola
Azienda Ospedaliera Universitaria Senese ( Site 0705), Siena
University of Wisconsin- Madison Carbone Cancer Center ( Site 0130), Madison
Mayo Clinic Rochester - St. Mary's Hospital ( Site 0117), Rochester
Texas Oncology-Tyler ( Site 8003), Tyler
Texas Oncology-Memorial City ( Site 8006), Houston
Seconda Universita degli Studi di Napoli ( Site 0704), Napoli
Kaohsiung Chang Gung Memorial Hospital ( Site 1203), Kaohsiung City
Arizona Oncology Associates, PC- HAL ( Site 8001), Tempe
UCLA Hematology/Oncology -Santa Monica ( Site 0108), Santa Monica
University of California San Francisco ( Site 0111), San Francisco
University of California Davis Comprehensive Cancer Center ( Site 0137), Sacramento
Azienda Ospedaliera Papardo ( Site 0706), Messina
Northwest Cancer Specialists, P.C. ( Site 8000), Vancouver
The Loginov Moscow Clinical Scientific Center ( Site 1008), Moscow
N.N. Blokhin NMRCO ( Site 1000), Moscow
National University Hospital ( Site 1901), Singapore
National Cancer Centre Singapore ( Site 1900), Singapore
SBHI Leningrad Regional Clinical Hospital ( Site 1001), Saint Petersburg
St Petersburg City Clinical Oncology Dispensary ( Site 1002), Saint Petersburg
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1005), Kazan'
Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1003), Ufa
Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site, Omsk
Yale University School of Medicine ( Site 0100), New Haven
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0112), Hackensack
The Ottawa Hospital ( Site 0306), Ottawa
Sunnybrook Health Science Centre ( Site 0304), Toronto
Princess Margaret Cancer Centre ( Site 0309), Toronto
CIUSSS du Saguenay-Lac-St-Jean ( Site 0305), Chicoutimi
Jewish General Hospital ( Site 0307), Montreal
CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0310), Montreal
Prince of Wales Hospital ( Site 1801), Hong Kong
Queen Mary Hospital ( Site 1800), Hong Kong
St James Hospital ( Site 2200), Dublin
Mid Western Cancer Centre ( Site 2201), Limerick
Fondazione Policlinico Universitario A. Gemelli ( Site 0703), Roma
National Cancer Center Hospital ( Site 2001), Tokyo
The Cancer Institute Hospital of JFCR ( Site 2000), Tokyo
MED-POLONIA Sp. z o.o. ( Site 0907), Poznan
Dolnoslaskie Centrum Onkologii. ( Site 0993), Wroclaw
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warsaw
MPOC ( Site 2310), Groenkloof Pretoria
Univ. Pretoria and Steve Biko Academic Hospitals ( Site 2315), Pretoria
Asan Medical Center ( Site 0801), Songpa-gu
Seoul National University Hospital ( Site 0800), Seoul
Severance Hospital Yonsei University Health System ( Site 0802), Seoul
Samsung Medical Center ( Site 0805), Seoul
Hospital General Universitari Vall d Hebron ( Site 1100), Barcelona
Cambridge University Hospitals NHS Trust ( Site 1306), Cambridge
University College London Hospital NHS Foundation Trust ( Site 1308), London
Derriford Hospital ( Site 1301), Plymouth
Merck Sharp & Dohme LLC
INDUSTRY